NCT01700179View on ClinicalTrials.gov

Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Chronic Hepatitis C Infection
Interventions
DRUG

ACH-0143102

DRUG

Ribavirin

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY